Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.94 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.94 |
| ▸ | MAPT | P10636 | 3/20 | 0.94 |
| ▸ | TSHR | P16473 | 3/20 | 0.94 |
| ▸ | POLB | P06746 | 3/20 | 0.94 |
| ▸ | NPC1 | O15118 | 2/20 | 0.94 |
| ▸ | HPGD | P15428 | 2/20 | 0.94 |
| ▸ | HTT | P42858 | 2/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.94 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.94 |
| ▸ | LMNA | P02545 | 1/20 | 0.94 |
| ▸ | TP53 | P04637 | 1/20 | 0.94 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.94 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.94 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.94 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | XBP1 | P17861 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13366895 | 1.00 | RAB9A (0.94) | RAB9AKDM4EMAPTTSHRPOLB | |
| SCHEMBL60258 | 1.00 | RAB9A (0.94) | RAB9AKDM4EMAPTTSHRPOLB | |
| SCHEMBL13366830 | 1.00 | RAB9A (0.94) | RAB9AKDM4EMAPTTSHRPOLB | |
| SCHEMBL61215 | 1.00 | RAB9A (0.94) | RAB9AKDM4EMAPTTSHRPOLB | |
| SCHEMBL15540128 | 0.97 | MAPT (1.00) | RAB9AKDM4EMAPTTSHRPOLB | |
| SCHEMBL29675943 | 0.97 | MAPT (1.00) | RAB9AKDM4EMAPTTSHRPOLB | |
| SCHEMBL18417992 | 0.84 | SMN1; SMN2 (0.67) | RAB9AKDM4EMAPTTSHRPOLB | |
| SCHEMBL18462258 | 0.84 | NPSR1 (0.67) | RAB9AKDM4EMAPTTSHRPOLB | |
| SCHEMBL18417989 | 0.84 | SMN1; SMN2 (0.67) | RAB9AKDM4EMAPTTSHRPOLB | |
| SCHEMBL55962 | 0.83 | MAPT (0.65) | RAB9AKDM4EMAPTTSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963475-B2 | Anthracene-9, 10-dione dioxime compound prodrugs and their uses | BETA CAT PHARMACEUTICALS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963475-B2 | Anthracene-9, 10-dione dioxime compound prodrugs and their uses | BETA CAT PHARMACEUTICALS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170334936-A1 | ANTHRACENE-9, 10-DIONE DIOXIME COMPOUND PRODRUGS AND THEIR USES | Iterion Therapeutics, Inc. | 2017-11-23 | — | — | US | disclosed |
| US-20170334936-A1 | ANTHRACENE-9, 10-DIONE DIOXIME COMPOUND PRODRUGS AND THEIR USES | Iterion Therapeutics, Inc. | 2017-11-23 | — | — | US | disclosed |
| US-9725473-B2 | Anthracene-9, 10-dione dioxime compound prodrugs and their uses | BETA CAT PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725473-B2 | Anthracene-9, 10-dione dioxime compound prodrugs and their uses | BETA CAT PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170029450-A1 | ANTHRACENE-9, 10-DIONE DIOXIME COMPOUND PRODRUGS AND THEIR USES | Iterion Therapeutics, Inc. | 2017-02-02 | — | — | US | disclosed |
| US-20170029450-A1 | ANTHRACENE-9, 10-DIONE DIOXIME COMPOUND PRODRUGS AND THEIR USES | Iterion Therapeutics, Inc. | 2017-02-02 | — | — | US | disclosed |
| WO-2010059142-A1 | ANTHRAQUINONE DIOXIMES AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029450-A1 | ANTHRACENE-9, 10-DIONE DIOXIME COMPOUND PRODRUGS AND THEIR USES | ACR, TOP2B, TOP2A | RAB9A 905/4885KDM4E 1909/4885MAPT 4739/4885 |
| US-20170334936-A1 | ANTHRACENE-9, 10-DIONE DIOXIME COMPOUND PRODRUGS AND THEIR USES | ACR, TOP2B, TOP2A | RAB9A 905/4885KDM4E 1909/4885MAPT 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.